eMedicine Specialties > Sports Medicine > Foot and Ankle

Metatarsalgia: Treatment & Medication

Author: Britt A Durham, MD, Director of Risk Management, Assistant Professor, Department of Emergency Medicine, King-Drew Medical Center and University of California at Los Angeles; CFO of Durcress Medical Group
Coauthor(s): Daniel Kaplan, MD, Assistant Professor, Department of Orthopedics, University of California Irvine
Contributor Information and Disclosures

Updated: Nov 1, 2007

Treatment

Acute Phase

Rehabilitation Program

Physical Therapy

The initial treatment includes regular icing and application of a pressure bandage (or RICE: rest, icing, compression, and elevation). Recommend non–weight-bearing ambulation for the first 24 hours, after which passive range-of-motion (ROM) and ultrasound treatments can be initiated. The use of metatarsal pads and other orthotic devices may provide relief, even in the early phases of treatment.6,11

Rehabilitation begins on the first day of injury, with the goal of restoring normal ROM, strength, and function. Long-axis distraction and dorsal/plantar glides of the metatarsophalangeal joint are self-mobilization techniques that can be used throughout the treatment process.

Occupational Therapy

Semi-rigid orthoses worn in supportive shoes have been shown to be effective treatment for metatarsalgia.11 Supportive shoes worn alone, with or without soft orthoses, have not been shown to provide adequate pain relief.

Medical Issues/Complications

The patient should avoid disrupting the healing process; rather, the patient should perform stretching and strengthening exercises carefully. Likewise, the patient’s return to higher-level activity should be pursued gradually and with caution to prevent reinjury. However, this obvious decreased level of activity may not be acceptable to some athletes. The practitioner may need to reinforce the relationship between the pain and the activity and discourage the athlete from trying to run in spite of the pain.

Surgical Intervention

Successful metatarsal pain outcomes have been reported with oblique osteotomy.12 The better outcomes are attributed to improved techniques to facilitate precise metatarsal positioning in different planes.

Other Treatment

  • Removing the callus (plantar keratosis) is not advised because the callus is a response to pressure and is not the primary disease. Temporary relief can be achieved by shaving down the callus; however, the clinician should avoid causing bleeding from excessive debridement and from the use of acids and other chemicals.
  • If the patient's symptoms are acute with a short duration, abnormal pronation of the subtalar joint can be the primary etiology. Use orthotic devices in these cases. Chronic symptoms respond better to a metatarsal bar that can be added to the running or athletic shoe.
  • Individuals with a pes cavus foot type who experience pain from metatarsalgia respond well to an orthotic device that provides total contact to the medial longitudinal arch because preventing collapse of the arch reduces the stress on the metatarsal heads. Patients with a Morton toe respond well to a rigid orthotic with an extension underneath the first metatarsal bone.

Recovery Phase

Rehabilitation Program

Physical Therapy

The primary focus of treatment is restoration of normal foot biomechanics and relief of pressure in the symptomatic area. Therapy must allow the inflammation to subside or resolve by relieving the repeated excessive pressure.

Once the individual is pain free, initiate isometric, isotonic, and isokinetic strengthening exercises. Passive ROM exercises can progress to active exercises as the inflammation resolves. Therapy to increase dorsiflexion ROM allows improved forward progression of the tibia over the foot, with reduced stress on the forefoot. Strengthening the toe flexor muscles may allow for greater weight-bearing capacity on the toes.

Recreational Therapy

Swimming is an excellent exercise for maintaining physical conditioning while the patient is in a restricted weight-bearing phase of healing.

Other Treatment (Injection, manipulation, etc.)

Patients with an interdigital neuroma component of injury can benefit from a nerve block in combination with administration of long-acting steroids. Individuals with primary metatarsalgia receive little benefit from such injections.

Maintenance Phase

Rehabilitation Program

Physical Therapy

As the inflammation subsides, an orthotic device is often the only intervention that is required to maintain normal mechanical function. These orthoses are necessary to distribute force away from the site of injury. Patients should continue self-mobilization exercises, including long-axis distraction and dorsal/plantar glides.

Surgical Intervention

Shoe modification with an orthosis may be the only treatment required for metatarsalgia. In severe cases, surgical realignment of the metatarsal bones may be required to balance weight bearing among the metatarsal heads.

In cases where conservative treatment has failed to provide relief of symptoms, surgical intervention may be required, including operative synovectomy, arthroplasty, wedge osteotomies of the metatarsal bases, ligamentous release, and tendon transfer.

Many types of osteotomies have been described as possible surgical interventions for metatarsalgia.12,13 Success and complications rates vary. The Weil osteotomy of the second and third metatarsals has been shown to be an effective and safe procedure for the treatment of central metatarsalgia.13

Consultations

Consider referral to an orthopedic specialist if no improvement has been achieved after 3 months of treatment.

Other Treatment

The high pressure under the metatarsal heads can be reduced by applying metatarsal pads. In a double-blind study, tear-drop shaped, polyurethane metatarsal pads were applied by experienced physiatrists to a total of 18 feet.6  As a result, there were significantly decreased maximal peak pressures and pressure time intervals during exercise that correlated with better pain and function outcomes.

Medication

Nonsteroidal anti-inflammatory drugs, such as ibuprofen, are useful for the symptomatic relief of the pain of metatarsalgia; however, these agents rarely provide a long-term solution.

Nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDS are most commonly used for the relief of mild to moderate pain. Although the effects of these agents in the treatment of pain tend to be patient specific, ibuprofen is usually the drug of choice (DOC) for initial therapy. Options include ketoprofen and naproxen and many other NSAIDs.


Ibuprofen (Motrin, Ibuprin)

DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Adult

600-800 mg PO bid/tid

Pediatric

20-40 mg/kg/d PO divided qid

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; monitor PT duration closely (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently.

Documented hypersensitivity; patients with peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, or high risk of bleeding

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Category D in third trimester of pregnancy; caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function; caution in the presence of anticoagulation abnormalities or during anticoagulant therapy


Ketoprofen (Oruvail, Actron, Orudis)

For relief of mild to moderate pain and inflammation.

Small dosages are initially indicated in small and elderly patients and in those with renal or liver disease. Doses over 75 mg do not increase therapeutic effects. Administer high doses with caution, and closely observe patient for response.

Adult

25-50 mg PO q6-8h prn; not to exceed 300 mg/d

Pediatric

<3 months: Not established
3 months to 12 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; monitor PT duration closely (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently.

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Category D in third trimester of pregnancy; caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function; caution in the presence of anticoagulation abnormalities or during anticoagulant therapy


Naproxen (Anaprox, Naprelan, Naprosyn, Anaprox)

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis

Adult

500 mg PO, followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; monitor PT duration closely (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; patients with peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Category D in third trimester of pregnancy; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug.

More on Metatarsalgia

Overview: Metatarsalgia
Differential Diagnoses & Workup: Metatarsalgia
Treatment & Medication: Metatarsalgia
Follow-up: Metatarsalgia
References

References

  1. Hockenbury RT. Forefoot problems in athletes. Med Sci Sports Exerc. Jul 1999;31(7 suppl):S448-58. [Medline].

  2. Safran MR, McKeag DB, Van Camp SP, eds. The foot: endurance events, marathon. Manual of Sports Medicine. Philadelphia, Pa: Lippincott-Raven; 1998:485, 558-9.

  3. McPoil TG, McGarvey T. The foot in athletics. In: Hunt GC, McPoil TG, eds. Clinics in Physical Therapy: Physical Therapy for the Foot and Ankle. 2nd ed. New York, NY: Churchill Livingstone; 1995:207-35.

  4. Quirk R. Metatarsalgia. Aust Fam Physician. Jun 1996;25(6):863-5; 867-9. [Medline].

  5. Steinberg GG, Akins CM, Baran DT, eds. Metatarsalgia. Orthopedics in Primary Care. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:284-7.

  6. Kang JH, Chen MD, Chen SC, Hsi WL. Correlations between subjective treatment responses and plantar pressure parameters of metatarsal pad treatment in metatarsalgia patients: a prospective study. BMC Musculoskelet Disord. 2006;7:95. [Medline][Full Text].

  7. Tóth K, Huszanyik I, Kellermann P, Boda K, Róde L. The effect of first ray shortening in the development of metatarsalgia in the second through fourth rays after metatarsal osteotomy. Foot Ankle Int. Jan 2007;28(1):61-3. [Medline].

  8. Endres S, Quante M. Oedema of the metatarsal heads II-IV and forefoot pain as an unusual manifestation of Lyme disease: a case report. J Med Case Reports. 2007;1:44. [Medline][Full Text].

  9. Iagnocco A, Coari G, Palombi G, Valesini G. Sonography in the study of metatarsalgia. J Rheumatol. Jun 2001;28(6):1338-40. [Medline].

  10. Yu JS, Tanner JR. Considerations in metatarsalgia and midfoot pain: an MR imaging perspective. Semin Musculoskelet Radiol. Jun 2002;6(2):91-104. [Medline].

  11. Chalmers AC, Busby C, Goyert J, Porter B, Schulzer M. Metatarsalgia and rheumatoid arthritis--a randomized, single blind, sequential trial comparing 2 types of foot orthoses and supportive shoes. J Rheumatol. Jul 2000;27(7):1643-7. [Medline].

  12. Kennedy JG, Deland JT. Resolution of metatarsalgia following oblique osteotomy. Clin Orthop Relat Res. Dec 2006;453:309-13. [Medline].

  13. O'Kane C, Kilmartin TE. The surgical management of central metatarsalgia. Foot Ankle Int. May 2002;23(5):415-9. [Medline].

Further Reading

Keywords

overuse injury, pain in the forefoot, forefoot injuries, interdigital neuroma, metatarsophalangeal synovitis, avascular necrosis, sesamoiditis, inflammatory arthritis, edema of the metatarsal heads

Contributor Information and Disclosures

Author

Britt A Durham, MD, Director of Risk Management, Assistant Professor, Department of Emergency Medicine, King-Drew Medical Center and University of California at Los Angeles; CFO of Durcress Medical Group
Britt A Durham, MD is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Daniel Kaplan, MD, Assistant Professor, Department of Orthopedics, University of California Irvine
Daniel Kaplan, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, Arthroscopy Association of North America, Association of Pediatric Program Directors, California Medical Association, and Western Orthopaedic Association
Disclosure: Nothing to disclose.

Medical Editor

Anthony J Saglimbeni, MD, Staff Physician, Family Practice Residency, Medical Director, Center for Sports Medicine, O'Connor Hospital; Private Practice
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood
Disclosure: Nothing to disclose.

CME Editor

Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital
Jon B Whitehurst, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

Chief Editor

Sherwin SW Ho, MD, Associate Professor, Department of Surgery, Section of Orthopedic Surgery and Rehabilitation Medicine, University of Chicago
Sherwin SW Ho, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.